HUBEI PROVINCE, CHINA--(Marketwire - November 05, 2007) - Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, announced today revised full year 2007 revenue guidance of $25.1 MM -- a 58% increase over 2006 revenue. The Company has also provided updated full year 2008 revenue guidance of $56.7 MM -- a 126% increase over anticipated 2007 revenue. The 2008 revenue guidance is predicated on the reopening of two subsidiaries (Jiangling Benda and Yidu Benda) by the end of 2007.
